Intermediatebiotechnology
Genetic Testing
Overview
Genetic testing analyzes DNA for health information: diagnostic (confirming disease), carrier (reproductive risk), predictive/presymptomatic (Huntington's, BRCA), prenatal (NIPT, amniocentesis), newborn screening, and pharmacogenomic. Methods span single-gene tests to exome/genome sequencing. Results need careful interpretation: pathogenic vs VUS vs benign, penetrance, and the right not to know.
Learning objectives
- List test types and their purposes
- Explain NIPT vs invasive prenatal testing
- Interpret variant classifications
- Discuss direct-to-consumer testing limits
Test types
Diagnostic: does this patient have the suspected genetic condition? Carrier: are prospective parents carriers (CF, Tay-Sachs panels)? Predictive: will disease develop (Huntington's, BRCA1/2)? Prenatal: NIPT (cell-free fetal DNA screening) vs diagnostic amniocentesis/CVS. Newborn screening: biochemical/genetic panels for treatable conditions (PKU).
Screening (NIPT) estimates risk; only diagnostic tests (amnio/CVS) confirm.
Methods
Single-gene/Sanger (targeted), gene panels (NGS, e.g., 100-gene cardiomyopathy panel), exome (~1-2% of genome, most coding disease variants), genome (everything, including interpretation burden). Chromosomal microarray detects CNVs. Choice balances yield, cost, and VUS burden.
Most Mendelian disease variants are coding: exome captures ~85% of diagnoses at a fraction of genome cost.
Interpreting results
ACMG classes: pathogenic, likely pathogenic, VUS (uncertain), likely benign, benign. VUS are common and anxiety-provoking; most are eventually downgraded. Penetrance and expressivity modulate risk; a pathogenic BRCA1 variant is not a cancer diagnosis.
Variants of uncertain significance should not drive irreversible medical decisions.
Direct-to-consumer
23andMe/AncestryDNA: genotyping chips (not sequencing) with limited health reports (FDA-authorized for a few variants: BRCA founder mutations, MUTYH). Limitations: incomplete variant coverage, no clinical interpretation, privacy concerns (data sales, law-enforcement access), and ancestry estimates that are statistical, not definitive.
DTC results need clinical confirmation before medical action: false positives/negatives occur.
Key points
- Types: diagnostic, carrier, predictive, prenatal, newborn, pharmacogenomic
- NIPT screens; amniocentesis/CVS diagnose
- ACMG classes: pathogenic -> benign; VUS needs caution
- DTC tests are limited and need clinical confirmation
Common misconceptions
✓ Truth: Penetrance is often incomplete; risk is probabilistic, not certain (except fully penetrant like Huntington's).
✓ Truth: It covers genetic risk only; environment, lifestyle, and chance dominate most disease.
Practice questions
Q1. Amniocentesis differs from NIPT in being
- Earlier
- Diagnostic rather than screening
- Risk-free
- Cheaper
Amnio/CVS analyze fetal cells directly: definitive but with small miscarriage risk.
Q2. A VUS result means the variant is
- Pathogenic
- Of uncertain significance: not actionable alone
- Benign
- Absent
Uncertain significance: manage by phenotype and family data, not the VUS.
Q3. Newborn screening primarily targets
- Adult-onset diseases
- Treatable early-onset conditions like PKU
- Ancestry
- Athletic ability
Screening is justified when early treatment changes outcomes.
Click a question to reveal the answer and explanation.
Frequently asked questions
What is non-invasive prenatal testing?
Sequencing cell-free fetal DNA in maternal blood to screen for trisomies 21/18/13 from ~10 weeks.
Should VUS guide surgery?
No: uncertain variants should not prompt prophylactic surgery; surveillance and family studies are appropriate.
What is GINA?
The US Genetic Information Nondiscrimination Act: bars health insurers/employers from using genetic data (not life/disability insurance).